Randomized placebo-controlled trials (RCTs) are standard for assessing efficacy and safety of treatments. We pursued preliminary indications that some factors are associated differentially with responses to placebo or drugs in RCTs for bipolar mania. We meta-analysed data from RCTs to assess influences of study-site count, subjects' age, sex distribution, diagnostic subgroups, clinical features, trial-completion rates, and publication year on mean difference (MD) in mania ratings between intake and final assessments. In 38 RCTs involving 3812 placebo-treated and 6988 drug-treated patients, symptomatic improvement was similar in placebo arms of trials of effective (6.77, 95 % CI 5.77-7.76) and ineffective (7.61, 95 % CI 5.47-8.75) drugs. Lesser placebo responses (MD) and greater drug-placebo differences (Hedges' g) were associated with fewer study sites, younger patients ' age, and male sex. More patients with initial psychotic features and more trial completion in drug arms were associated with greater drugassociated improvement (MD) and drug-placebo contrast (Hedges' g), whereas more mixed-state diagnoses decreased both measures. Identifying modifying factors can support more efficient and cost-effective designs of therapeutic trials. In trials for mania, fewer sites may limit placebo response and enhance drug-placebo contrasts.
Introduction
Randomized, placebo-controlled, trials (RCTs) are standard for testing efficacy and safety of medical treatments. However, ethical, clinical, and practical concerns arise in the use of placebos, particularly when they interrupt ongoing active treatment or make subject recruitment into experimental trials difficult (Charney et al. 2002 ; Ehni & Wiesing, 2008 ; Kotzalidis et al. 2008 ; Vieta & Carne, 2005) . Nevertheless, use of placebos as controls in experimental therapeutic trials continues to be accepted and even required by some regulatory agencies including the US Food and Drug Administration (FDA). Alternative trial designs, such as comparisons of experimental to established treatments usually require large numbers of subjects in attempts to detect small differences. Such comparison designs also risk random and potentially misleading findings of 'non-significant differences '. Spurious results are especially likely in trials with limited quality control in subject selection and clinical ratings, particularly in disorders in which non-specific or 'placebo ' response rates typically are moderately high, including mania (Charney et al. 2002 ; Kotzalidis et al. 2008) . With 'non-inferiority ' trials, there is no expected difference in efficacy between test treatments (null hypothesis), and sample size cannot be guided by statistical power analysis, so that non-rejection of the null hypothesis may be inconclusive, even with large samples.
As therapeutic innovation in psychiatry increases, more controlled treatment trials are needed, resulting in greater pressure to recruit patient-subjects quickly and efficiently in large samples that may vary in quality control. Accordingly, the costs of conducting such trials, as well as the major challenges of maintaining scientific quality control are increasing, with the risk of loss of sensitivity and a paradoxical increase in costs as well as increased assessment variance by requiring very large samples. Quality control is particularly difficult in increasingly common international trials carried out in geographically separate and heterogeneous sites. These circumstances provide increasing challenges to limiting variance in subject recruitment, diagnosis, and ongoing assessment, as well as limiting typically high dropout rates with loss of data. Such problems appear to be reflected in indications that, even in severe psychiatric disorders including schizophrenia and mania, clinical change during placebo treatment has been rising in recent years (Kemp et al. 2010 ; Sysko & Walsh, 2007 ; Vieta & Cruz, 2008) . A recent collaborative conference involving the International Society for CNS Clinical Trials and Methodology (ISCTM) and the International Society for CNS Drug Development (ISCDD) reviewed factors associated with placebo-associated responses in trials (Kemp et al. 2010) . Factors considered included : longer duration of current acute illness episodes, effects of 'rescue ' medications such as sedatives, variability in assessments, lack of optimized drug-dosing, as well as inconsistent medication compliance and protocol adherence (Kemp et al. 2010) . Pardoxically, imperfect control of variance and typically modest effect sizes (drug-placebo contrasts) in the conduct of trials encourages larger samples derived from more collaborating sites, but at greater costs and with greater risk of increasing variance with the risk of regression-to-the-mean in both placebo and drug arms of RCTs (Kemp et al. 2010) . Such circumstances have uncertain impact on the quest for larger or more stable drug-placebo contrasts. It is also an ethical truism that larger trials require exposing more patients to inactive placebo treatment.
We hypothesize that identifying characteristics of research subjects and of trial designs associated with smaller placebo responses and larger drug-placebo contrasts, as well as identifying subgroups that may be particularly treatment-responsive or -tolerant (or the opposite), will have value in optimizing trial design. Such considerations should limit the complexity of trials and decrease their expense, duration, and the number of persons exposed to potentially inactive treatments or placebos, as well as facilitating subject recruitment and retention (Charney, 2000 ; Charney et al. 2002 ; Kent & Hayward, 2007 ; Kotzalidis et al. 2008) . Moreover, placebo-response rates can influence observed drug-placebo differences in trials, and inferences about efficacy of particular treatments relevant to rational or evidence-based clinical treatment (Kent & Hayward, 2007) .
In response to the many challenges of including placebo-controls in treatment trials, we conducted a meta-analysis of RCTs of single treatments in acute mania. In this analysis, we identified clinical and trialdesign factors that may be associated with responses to randomized placebo or drug treatments. In particular, we sought factors that might enhance drugplacebo contrasts, or at least limit placebo response, as a contribution to improving the design of experimental therapeutic trials.
Methods

Data sources
We conducted meta-analyses of all available randomized, placebo-controlled monotherapy trials for acute mania in patients with manic or mixed phases of type I bipolar disorder (BPD). We identified reports through computerized searches of the PubMed/ Medline ; ClinicalTrials.gov ; Cochrane Central Register of Controlled Trials ; Controlled-trials.com ; and EMBASE/Excerpta Medica databases (search terms : ' bipolar ', 'mania ', 'placebo ', ' trial', and ' names' of individual anticonvulsant, antipsychotic, or other drugs tested in mania, up to 12 January 2010). We extended the search by reviewing bibliographies of reports identified, as well as reports of presentations at meetings of the American Psychiatric Association (APA), American and European Colleges of Neuropsychopharmacology, and the International Conference on Bipolar Disorder. We also consulted study investigators and representatives and scientists of pharmaceutical companies that produce antimanic agents for leads to other trial reports and for access to data missing from identified reports.
Study selection and data extraction
We included only trials involving a placebo and one or more active treatments or doses, assigned randomly, to test efficacy among consenting adults diagnosed with acute mania or mixed states of type I BPD by definitions in the APA Diagnostic and Statistical Manual (DSM-III to DSM-IV-TR) or Research Diagnostic Criteria (RDC) (APA, 2000 ; Spitzer et al. 1978) . We excluded trials involving patients diagnosed with unspecified BPD (NOS), BPD II, or schizoaffective disorders, and trials permitting use of psychotropic agents other than modest doses of sedatives or hypnotics (benzodiazepines or chloral hydrate). For quality control, required trial data were extracted by two scientists (A. Yildiz and S. Ö zer) .
Information extracted and evaluated included study-site counts, sample sizes in each trial arm, based on intent-to-treat (ITT) principles (i.e. patients with at least one post-randomization assessment), mean age of subjects, sex distribution, initial diagnosis (mania vs. manic-depressive mixed state), presence of psychotic features, baseline illness severity ratings (percent of maximum attainable mania scale scores), nominal trial duration, rates of trial completion, source of support, and year of reporting. The primary outcome of interest was mean change in mania ratings between intake and last observation, expressed as mean difference (MD), considered separately for drug and placebo arms of each trial. We also considered drug-placebo differences in outcomes, expressed as Hedges' g, based on standardized MD between changes in mania ratings with drug vs. placebo. The main secondary outcome measure was rate of response (proportion of subjects with o50 % improvement in mania ratings) with drug and placebo (Tohen et al. 2009 ). Ratings of clinical change were based on the 11-item Young Mania Rating Scale (YMRS ; maximum score=60) used in 80.4 % of trials, or the 11-item Mania Rating Scale (MRS ; maximum score=52), which are similar in scoring characteristics and ability to detect treatment effects Vieta, 2003 ; Young et al. 1978) . We examined the primary outcome measure (MD for placebo or drugs ; Hedges ' g for drug-placebo contrasts) for association with site counts, mean age, percent men, initial diagnosis ( % manic vs. mixed), proportion ( %) with psychotic features, trial completion rates ( %), and publication year.
Meta-analyses
We combined data across trials by meta-analytial modelling of mean changes in mania ratings during randomized treatment with placebo or drugs. When standard deviations (S.D.) for changes in score were not reported, we estimated them by a standard formula (Whitley & Ball, 2002) . Computed values are shown with 95 % confidence intervals (CIs). Since the studies analysed involved different investigators and varied environments, we used random-effects meta-analytical modelling, with or without evidence of inter-study heterogeneity as evaluated with preliminary Q tests (Borenstein et al. 2009 ).
We examined potential effects of the previously stated parameters on the primary, continuous outcome measures of MD for drug arms and placebo arms ; and Hedges' g for drug-placebo differences by using unrestricted maximum-likelihood, mixed-effects metaregression modelling to generate a slope function (b coefficient) that reflects the influence of each factor on the corresponding outcome measure (Berkey et al. 1995) . MD for change in mania ratings between baseline and end-point in placebo arms and drug arms of trials are considered placebo effect and drug effect, respectively ; Hedges' g indicates adjusted mean drug-placebo difference in change in mania ratings (treatment effect). To limit risk of false-positive (type I) errors, we corrected a=0.05 by dividing it with the number of moderator variables (n=7), requiring pf0.007 (0.05/7) to establish statistical significance.
Trials with negative results (statistical nonseparation of drug vs. placebo) are less likely to be published than those with statistically significant drug-placebo contrasts. To limit such reporting bias, we performed a comprehensive literature search and included data from unpublished reports. Then, we applied the funnel-plot method (pooled MD vs. its standard error) to evaluate presence of reporting bias (Sterne & Egger, 2001 ). We also estimated Orwin's failsafe N values (number of additional hypothetical studies with zero-effect required to make the pooled effects derived from meta-analysis trivial, i.e. effect size f0.10) ; larger fail-safe N indicates less likelihood of publication bias (Orwin, 1983) . Finally, we employed Duval & Tweedie's trim-and-fill approach to calculate a best-estimate of unbiased effect size by removing extremely small studies from the funnel plot individually until the plot became symmetrical about the (new) pooled effect size (Duval & Tweedie, 2000) . We used Biostat commercial software for metaanalyses (Comprehensive Meta-Analysis, version 2.2 ; BioStat Inc., USA).
Results
Characteristics of trials and subjects
We identified 38 studies yielding 56 comparisons (13 with negative results) of 17 active drugs vs. placebo, involving a total of 5929 patients randomized to a placebo [ Table 1 ]. Corrected for duplicate counting of placebo-arm patients in multi-arm trials, a total of n=3812 patient-subjects were randomized to placebo arms of the trials considered, and had at least one postrandomization assessment during protocol-guided treatment (ITT samples). Most studies (34/38=89.5 %) Also based on meta-analytical pooling, the overall, secondary outcome measure of responder rate (improving o50 %) was substantial over 3 wk, at 30.8 % (95 % CI 28.6-33.2) for all placebo-treated patients. For trials involving effective drugs, pooled responder rates were 48.3 % (95 % CI 46.2-50.4) in drug arms and 30.7 % (95 % CI 28.1-33.3) in placebo arms -a 1.6-fold difference. The pooled responder rate in drug arms of ineffective agents was much lower, as expected, at 30.8 % (95 % CI 26.2-35.9), and close to the corresponding placebo-associated responder rate of 31.6 % (95 % CI 26.6-37.2). Notably, however, placebo responder rates in trials of effective and ineffective drugs (agents with non-significant overall drug-placebo contrasts) were nearly identical (30.7 %, 95 % CI 28.1-33.3 vs. 31.6 %, 95 % CI 26.6-37.2, respectively).
These findings indicate that most of the contrast in outcomes of trials of apparently effective vs. ineffective agents was due to marked differences in drug response, and that differences in placebo responses were minor.
Factors associated with placebo responses
Factors of interest were tested for association with placebo effect based on changes in mania ratings (MD) in all placebo-treatment trial arms for which data were available, and included only once in the meta-regression modelling (Tables 2 and 3 ). For comparison, we considered the same factors for association with drug effect (also based on MD for change in mania ratings) as well as treatment effect (based on Hedges' g for effects of drug vs. placebo). For testing those associations of candidate factors with drug effect and treatment effect we considered only the 13 drugs found significantly more effective than placebo in a meta-analysis of individual drugs for bipolar mania (Yildiz et al. 2010) , in order to avoid potential confounding by drug ineffectiveness, which would influence the drug-associated benefit as well as observed drug and placebo differences. Regression modelling of drug effect involved only patients in drug arms, whereas modelling of treatment effect involved patients in both drug and placebo arms. However, reported proportions of patients given active drugs who completed each trial were also tested for association with treatment effect. Since most of the studies did not report subjects ' ages in each treatment arm separately, we used average age for entire study samples in corresponding regression models. Since seven preselected covariates were tested by meta-regression, statistical significance was set at two-tailed a=0.007.
Meta-regression modelling suggested that a lower number of collaborating study sites was strongly associated with lesser placebo-induced improvement of mania ratings (MD), and greater drug-placebo contrasts (Hedges ' g) (see Fig. 1 ). Of note, more study sites corresponded to larger patient samples, and with larger placebo effects (in 38 trials ; b=+0.06, 95 % CI 0.04-0.08, z=6.47, p<0.0001). Notably, however, site counts had no apparent association with drug-associated improvements in mania ratings (MD). Male sex was associated with lesser placebo effects, and greater treatment effects. On the contrary, younger mean age was associated with lesser placebo effects and greater drug-associated improvements, and correspondingly greater drug-placebo contrasts. Diagnostic subgroups (mania with or without psychotic features or manic vs. mixed states) had no apparent influence on placebo effects overall, although outcomes were rarely reported separately for such subgroups. However, presence of psychotic symptoms increased both observed effects of treatment over placebo and drug-associated benefit, whereas the proportion of cases with mixed state decreased both measures (Tables 2 and 3) .
More trial completers (lower dropout rates) in placebo arms was not related to improvements with placebo, but higher proportion of trial completion in drug arms was associated with both greater drugassociated benefit and drug-placebo contrast or treatment effect (Tables 2 and 3) . No outcome was associated with publication year, and there were too few MD, Mean difference ; N, number of comparisons included in corresponding regression models. Q model indicates the amount variance or heterogeneity in effect sizes predicted by the model. Effect-size measure is MD for placebo effects and drug effects ; and Hedges' g for drug-placebo contrast. Only effective drugs were considered for drug effect and drug-placebo contrast, but all available placebo arms were included for placebo effect. a For studies not reporting actual site numbers, they are estimated as twice that of the reported number of countries. b Mean age for the study sample was the moderator variable used for all three outcomes. c Meta-regression results after exclusion of outliers (two single-site tamoxifen trials with worsening of mania ratings with placebo). d Indicates non-significance after correction for multiple comparisons (adjusted p=0.05/7=0.007).
trials not supported financially by pharmaceutical manufacturers to test effectively for potential effects of sources of study support. However, exclusion of two small, academic, non-industrial, single-site trials with unusually low placebo effects led to a secular association of rising placebo effects in more recent years, as well as a secular effect of rising numbers of collaborating sites/trials (Fig. 1) .
Publication bias
Examination of funnel plots of the primary outcome (MD in placebo arms of trials vs. its standard error) Only effective drugs (>placebo) were considered for drug effects and drug-placebo differences (in 40-48 randomized, monotherapy trials), but all available placebo arms were included for placebo effect (31-38 trials ; unmatched numbers owing to multiple active treatments in some trials). Improvement is based on mean difference for placebo effects and drug effects, and Hedges' g for drug-placebo contrasts. a For studies not reporting actual site numbers, they are estimated as twice that of the reported number of countries. b Mean age for the study sample was the moderator variable used for all three outcomes. c There were no significant associations between publication year and any effect measure. However, exclusion of outliers (two single-site tamoxifen trials with worsening of mania ratings with placebo) indicated rising placebo-related improvements in recent years. indicated publication bias (Kendall's t=x0.26, z= 2.31, p=0.02). Orwin's fail-safe N was 2793, indicating that a very large number of studies with zero effect would need to be added to produce a trivial outcome, and that is very unlikely to have arisen by omission of overlooked reports. Finally, Duval & Tweedie's trimand-fill method did not identify any aberrant studies, and the summary effect remained unchanged (MD= 6.92, ).
Discussion
This is the first meta-analytical evaluation of patientcharacteristics or other trial-design factors for association with placebo and drug responses and drugplacebo contrasts (effect sizes) in RCTs for mania. After diligent searching to identify all available trials, we considered RCTs involving DSM-III or DSM-IV BPD patients in acute manic or mixed states, randomized to the placebo arms or drug arms of 38 studies with 56 drug-placebo contrasts, and reported on drug efficacy previously (Yildiz et al. 2010) . These RCTs indicated 13 effective (with statistically superior overall outcomes over placebo : 49 contrasts) and four ineffective (seven contrasts) candidate drugs. Factors associated with lesser placebo effects included : (a) fewer collaborating sites, (b) younger patients, and (c) higher proportion of men in placebo arms (Tables 2  and 3 ). Since some of these factors are potentially modifiable, their consideration in the design of treatment trials may help to limit sample sizes, placebo exposure, trial failures, financial costs, and generally yield trials that are more efficient and attractive to patients, their families, and physicians. To help with power and sample-size estimates for future treatment trials in mania, we considered responses following randomization to placebo or drug in 49 trials of the 13 effective antimanic agents. In these successful trials, the meta-analytically pooled MD between initial and final mania ratings was 6.77 scale points for placebo arms (n=3199), and 12.7 for drug arms (n=6075), indicating nearly 2-fold superiority of effective drugs over placebo. In secondary analyses, pooled responder rates ( % of patients showing o50 % improvement in mania ratings) were 30.7 % (n=2944) with placebo and 48.3 % (n=5827) with effective drugs, a somewhat lesser (1.6-fold) contrast. This moderate absolute difference of 17.6 % in the responder rates with drug vs. placebo is similar to an estimate of 18 % (41 % to drug vs. 24 % to placebo) in 38 RCTs involving 7323 participants for schizophrenia ). In earlier reviews of eight (Keck et al. 2000) and 21 (Sysko & Walsh, 2007) RCTs in acute mania, reported placebo responder rates averaged 23.0 % and 31.2 %, respectively, or close to our meta-analytical estimate of 30.8 % (95 % CI 28.6-33.2) across 38 studies with 56 drug-placebo contrasts (Yildiz et al. 2010 ).
An initially observed association between presence of psychotic symptoms and lesser placebo-induced improvements in mania ratings was not significant after correction for multiple comparisons. Yet, concurrent psychotic symptoms in mania seemed to enhance drug-associated benefit as well as drug-placebo contrasts (Tables 2 and 3 ). Moreover, a higher proportion of cases diagnosed with manic-depressive mixed states resulted in lesser treatment and drug effects, with no apparent effect on placebo-induced improvements in mania ratings (Tables 2 and 3 ). These observations regarding mixed states suggest a subgroup that is particularly difficult to treat, especially with an antimanic monotherapy, and a subgroup that may not appropriately be combined with mania . Paradoxically, although mixed states often are more severe or clinically challenging than relatively pure mania, their mania rating scores are often lower. This impression was sustained in the present findings, in that baseline mania ratings were lower with higher proportions of mixed-state patients in 52 trials with available data (b=x0.10, 95 % CI x0.13 to x0.06, z=x5.19, p<0.0001), with lesser corresponding improvements with drugs in 46 of the trials (b=+0.26, 95 % CI 0. 13-0.40, z=3.80, p=0.0002) . The observed impact of mixed states on trial outcomes suggests that such patients should be excluded from mania trials, or at least considered separately, ideally with assessments of depressive as well as manic symptoms . In general, we favour consideration of subgroups within trials in order to identify patients who are particularly responsive or tolerant to particular treatments (or not), as well as trials that continue to syndromal remission, and so can better differentiate speed of effect from actual efficacy.
Some observers have challenged the findings of available clinical trials on mania because of variable or low baseline severity of mania ratings among patients included. Initial mania scores in identified trials considered in this study were 39.2-65.4 % of maximum attainable scores, and fewer than half of the trials involved baseline mania scores of o50 % of maximum attainable scores. As we reported previously, greater initial manic symptom severity did not enhance observed drug-placebo contrasts, but instead, amplified benefit from the drugs selectively (Yildiz et al. 2010) . This association may reflect a more treatmentsensitive clinical subtype, or, more likely, the technical effect of greater apparent improvement with higher initial severity scores. That is, the 'law of initial values ' (more deviant initial assessments tend to yield greater change with interventions) may well apply to experimental therapeutics (Benjamin, 1963) .
When the present findings are considered together, they suggest a profile of manic patients less likely to improve with a placebo, or with greater drug-placebo contrasts, i.e. a greater likelihood of a successful trial outcome. Such characteristics included : (a) trials with fewer study sites (a particularly strong effect, presumably reflecting better quality control, and with fewer subjects), (b) younger age, (c) male sex, and (d) psychotic features. In addition, more completion of drug treatments was associated with greater benefit from drug and enhanced drug-placebo contrast.
A particularly notable finding of this study is that improvement during placebo treatment was substantially and selectively smaller with fewer collaborating sites. It challenges the recent trend towards more sites/trials (Fig. 1) . Indeed, some single-site trials in mania have reported very slight improvement, or even worsening with placebo treatment (Pope et al. 1991 ; Yildiz et al. 2008 ; Zarate et al. 2007 ). With such rare small trials omitted (Yildiz et al. 2008 ; Zarate et al. 2007) , we found evidence of a secular trend for increasing placebo effects over time, probably as a manifestation of rising numbers of study sites and patient-subjects. Further meta-regression after exclusion of the rare single-site studies with particularly small placebo effects (Yildiz et al. 2008 ; Zarate et al. 2007) , verified the observed associations between higher numbers of collaborating study sites and greater placebo-induced improvement in mania ratings (36 trials ; b=+0.06, 95 % CI 0.03-0.10, z=3.66, p=0.00025), as well as smaller drug-placebo contrasts (46 trials ; b=x0.05, 95 % CI x0.009 to x0.002, z=x2.86, p=0.004). Improvements observed during treatment with a placebo may reflect the natural course of a time-limited acute illness like mania, variance in relatively non-specific interventions related to clinical management, regression to mean outcome ratings, as well as an hypothesized ' placebo effect ' itself (Klosterhalfen & Enck, 2006 ). Yet, given the large variance in placebo responses in the trials considered here, despite nominally similar patients and diagnostic and assessment methods, it is likely that other factors are also involved. We propose that that ' noise ', arising from local and individual variation in the application of diagnostic and assessment methods and difficulties in maintaining high levels of inter-rater and inter-site reliability across geographically and culturally diverse sites tends to promote regression to average outcome ratings, as a major determinant of placebo response. We suggest that a simple means of mitigating such effects may be to employ fewer and more homogenous collaborating sites with better control over diagnostic and symptom assessments.
Although, the available data were not adequate to support a conclusive assessment, it is also possible that the sources of financial support for trials may affect their outcome. Most of the acute treatment trials in mania or mixed states identified for this study were sponsored by the manufacturers of the drugs tested, and only four were supported by non-profit-making organizations. Meta-analytically pooled improvement in mania ratings with placebo treatment in 34 industry-sponsored trials was 7.71 (95 % CI 7.08-8.35), compared to a far lower value of x2.92 (95 % CI x5.68 to x0.16) in only four trials with non-industry sponsorship. For drugs with significant overall drug-placebo contrasts, effect sizes in drug arms were comparable in 45 industry-sponsored trials (pooled MD=12.5, 95 % CI 11.8-13.3), and three non-industry-sponsored trials (pooled MD=15.8, 95 % CI 12. 1-19.6 ). The small number of non-industry-sponsored trials obviates a meaningful statistical comparison, the findings suggest that industrial funding was associated with relatively large placebo-related, but not with drug-related benefits in trials in acute mania. In turn, this effect may reflect the relatively larger numbers of sites and subjects in the pharmaceutical-sponsored trials.
Several limitations of this study should be noted. Randomization can protect against many subject selection biases in individual studies but not in metaregressions (Borenstein et al. 2009 ). As such, identified associations between study-level moderator variables and effect sizes are observational results, and cannot be presumed to be definitive. Further meta-analytical evaluation of identified categorical factors (young/ old, male/female, manic/mixed, psychotic/nonpsychotic, completer/non-completer) on the outcome measures was not possible since individual studies did not separately report on these potentially important subgroups. Similarly, dosing of rescue medications, exact durations of pre-randomization washout of previous treatments, and days in hospital during trials, as well as such clinical details as the numbers, types, durations, and severity of episodes of previous illness per study arm were not reported in most trials. We therefore, strongly encourage the inclusion of such information, with responses to drug and placebo in subgroups in future studies of acute mania and other major disorders.
In conclusion, meta-analysis and meta-regression modeling based on 56 comparisons of candidate drugs with placebo controls in 38 RCTs involving diverse BPD I patients in acute episodes of mania or mixed manic-depressive states indicated that a smaller number of collaborating sites was strongly associated with lesser responses to placebo treatment, with little influence on responses to effective drugs. We propose that this aspect of trial design is readily modified, and should improve the efficiency of RCTs, at least for mania. Further research on this, and other indicated factors may lead to more cost-effective and feasible trials, exposure of fewer persons to placebo or potentially ineffective treatments, and facilitate subject recruitment and retention.
